Skip to main content
Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now

Evexia Lifecare Ltd| Audited Standalone Q4 & FY26 Financial Results

Report Source

⬤9th May 26

Summary : Evexia Lifecare reported increased profits and revenue, but faces severe audit qualifications, including significant credit risks, valuation issues, and going concern doubts for a subsidiary.

Quarterly Report Analysis & Insights

Financial Disclosures

  1. Standalone FY26 Total Expenses: Rs. 10,429.48 Lakhs (FY25: Rs. 8,281.95 Lakhs).
  2. Consolidated FY26 Total Expenses: Rs. 10,807.70 Lakhs (FY25: Rs. 8,620.00 Lakhs).
  3. Significant credit risk identified in loans and trade receivables.
  4. Standalone FY26 Revenue from operations: Rs. 10,546.47 Lakhs (FY25: Rs. 8,388.68 Lakhs).
  5. Consolidated FY26 Revenue from operations: Rs. 11,027.50 Lakhs (FY25: Rs. 8,659.04 Lakhs).
  6. Standalone FY26 Net cash used in operating activities: Rs. (2,288.06) Lakhs (FY25: Rs. (592.78) Lakhs).
  7. Consolidated FY26 Net cash used in operating activities: Rs. (2,348.34) Lakhs (FY25: Rs. (441.37) Lakhs).
  8. Standalone FY26 Net cash from investing activities: Rs. 2,192.08 Lakhs (FY25: Rs. (1,451.43) Lakhs).
  9. Consolidated FY26 Net cash from investing activities: Rs. 5,267.73 Lakhs (FY25: Rs. (1,579.65) Lakhs).
  10. Standalone FY26 Cash & cash equivalents at year-end: Rs. 9.04 Lakhs (FY25: Rs. 2.92 Lakhs).
  11. Consolidated FY26 Cash & cash equivalents at year-end: Rs. 237.52 Lakhs (FY25: Rs. 62.41 Lakhs).
  12. Direct tax litigations and statutory compliance matters.
  13. Standalone FY26 Total Assets: Rs. 86,430.20 Lakhs (FY25: Rs. 83,440.20 Lakhs).
  14. Consolidated FY26 Total Assets: Rs. 87,341.88 Lakhs (FY25: Rs. 89,448.13 Lakhs).
  15. Standalone FY26 Net Worth: Rs. 43,714.10 Lakhs (FY25: Rs. 42,958.05 Lakhs).
  16. Consolidated FY26 Net Worth: Rs. 43,444.20 Lakhs (FY25: Rs. 45,956.80 Lakhs).
  17. Consolidated results include unaudited financial statements of six subsidiaries.

Corporate Overview

  1. India
  2. Tongo
  3. Significant credit risk in loans and trade receivables.
  4. Inability to determine fair valuation for unquoted investments.
  5. Subsidiary Kavit Edible Oil Limited faces going concern doubt.
  6. Instances of material misstatements and non-compliance.
  7. Lifecare and Edible Oil (via subsidiary) operations.
  8. Management believes tax litigations are contestable.
  9. Management believes FCCB extension has no material adverse impact.
  10. Lifecare
  11. Edible Oil (via subsidiary)
  12. Kavit Edible Oil Limited suspended manufacturing operations since March 2019.

Risk Factors

  1. Significant credit risk in loans receivables.
  2. Significant credit risk in trade receivables.
  3. Subsidiary faces going concern doubt.
  4. Material misstatements and missing documentation.

Key Drivers

  1. Net profit increased significantly year-on-year.
  2. Revenue from operations showed healthy growth.
  3. Investing cash flow turned positive.
  4. Cash and equivalents balance improved.

Auditor’s Report

  1. Qualified Opinion (Standalone and Consolidated)
  2. Loans receivables (Rs. 735.13 Lakhs) with significant credit risk, lacking expected credit loss assessment.
  3. Trade receivables (Rs. 2943.89 Lakhs) with significant credit risk, lacking expected credit loss assessment.
  4. Investments in unquoted equity shares (Rs. 87.39 Lakhs) with undetermined fair valuation.
  5. Subsidiary Kavit Edible Oil Limited has suspended operations, negative net worth, raising going concern doubt.
  6. Material misstatements, non-compliance, improper valuation, and missing documentation.
  7. Consolidated results include unaudited financial statements of six subsidiaries.
  8. Direct tax litigations and statutory compliance matters, considered contestable by management.

Board Commentary

  1. Significant credit risk in loans and trade receivables.
  2. Subsidiary Kavit Edible Oil Limited faces going concern doubt.
  3. Involved in direct tax litigations and statutory compliance matters.
  4. Extended FCCB conversion/redemption period from March 2026 to February 2028.

Corporate Governance

  1. Audit Committee is in place.
  2. Repetitive qualified audit opinion.
  3. Material misstatements and non-compliance with reporting framework.
  4. Inadequacies in recognition and measurement of provisions.
  5. Missing documentation and unverified significant transactions.

Management Discussion & Analysis

Future Strategy

  1. Extended Foreign Currency Convertible Bonds (FCCB) conversion/redemption period to February 2028.

Risk Control Measures

  1. Management considers direct tax litigations contestable.
  2. Management believes FCCB extension has no material adverse impact.

Critical Risks

  1. Significant credit risk in loans receivables (Rs. 735.13 Lakhs).
  2. Significant credit risk in trade receivables (Rs. 2943.89 Lakhs).
  3. Inability to fair value unquoted equity investments (Rs. 87.39 Lakhs).
  4. Subsidiary Kavit Edible Oil Limited has negative net worth and going concern doubt.
  5. Material misstatements, non-compliance, and missing documentation.
Evexia Lifecare Ltd - Quarterly Report Analysis & Insights